OncoMatch/Clinical Trials/NCT06051695
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Is NCT06051695 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including A2B694 and A2B543 for solid tumor, adult.
Treatment: A2B694 · A2B543 — The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Pancreatic Cancer
Ovarian Cancer
Mesothelioma
Biomarker criteria
Required: HLA-A loss of heterozygosity (LOH) of HLA-A*02
tissue demonstrating LOH of HLA-A*02 by NGS
Required: MSLN expression
solid tumors with MSLN expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received:
Received previous required therapy for the appropriate solid tumor disease as described in the protocol
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Cannot have received: solid organ transplant
Prior solid organ transplant
Lab requirements
Blood counts
adequate organ function as described in the protocol
Kidney function
adequate organ function as described in the protocol
Liver function
adequate organ function as described in the protocol
Has adequate organ function as described in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner Health · Gilbert, Arizona
- UCSD Moores Cancer Center · La Jolla, California
- UCLA Medical Center · Los Angeles, California
- Stanford University · Stanford, California
- Mayo Clinic · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify